Form Type and Filing Date: This is an 8-K Current Report filed by IDEXX Laboratories Inc on February 2, 2026, reporting events as of that same date. Item 2.02 - Results of Operations and Financial Condition: The filing indicates disclosure of results of operations and financial condition, though the specific financial details and earnings information are not fully visible in the provided document…

Our analysis rates this filing BULLISH. IDEXX demonstrates a fundamentally strong financial position with multiple positive indicators. Q4 2025 results exceeded typical growth expectations with 14% reported revenue growth and 18% EPS growth, indicating healthy margin expansion. The record…

Concern level: MODERATE (2.1/10). Key factors: Conservative 2026 guidance reflects moderating growth expectations (7.6%-9.6% reported revenue growth vs. 12% organic in 2025); No new high-severity risks identified in current filing; Risk score of 2.1 indicates minimal emerging concerns.

Notable risk changes: Strong Q4 2025 financial performance: 14% reported revenue growth (12% organic) with EPS of $3.08 up 18% reported and 17% comparable basis; Record instrument placements in Q4 with 1,900+ IDEXX inVue Dx placements and 12% YoY expansion of premium instrument installed base, indicating successful product adoption; Conservative 2026 guidance provided: Revenue growth of 7.6%-9.6% reported (7.0%-9.0%…

The model predicts IDXX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.